Skip to main content
SpringerLink
Log in

Economics of Serotonin 5-HT3 Antagonists

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Plosker GL, Benfield P. Granisetron: a pharmacoeconomic evaluation of its use in the prophyl axis of chemotherapy—inducednausea and vomiting. Pharmacoeconomics 1996; 9 (4): 357–74

    Article  PubMed  CAS  Google Scholar 

  2. O’Brien BJ, Rubsthoven J, Rocchi A, et al. Impact of chemotherapy— associated nausea and vomiting on patients’ functionalstatus and on costs: survey of five Canadian centres. Can Med Assoc J 1993; 149: 296–302

    Google Scholar 

  3. Jobet I, Zyguel S, Prugnaud JL. Evaluation economique des anti−5HT3: mise au point d’un modele d’étude. J Pharm Clin 1995; 14: 55–63

    Google Scholar 

  4. Johnson N, Bosanquet. Cost effectiveness of 5−hydroxytryptamine receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer Drugs 1995; 6: 243-9

    Article  PubMed  CAS  Google Scholar 

  5. Kirchner Y, Aapro M, Alberto P. The cost—effectiveness of granisetron compared to metoclopramide with dexamethasone [abstract 1315). Proc Am Soc Clin Oncol 1992; 11: 379

    Google Scholar 

  6. Jones AL, Lee GJ, Bosanquet N. The budgetary impact of 5−HT3 receptor antagonists in the management of chemotherapy—induced emesis. Eur J Cancer 1993; 29A (1): 51–6

    Article  Google Scholar 

  7. Ballatori E, Roila F, Berto P, et al. Cost and cost—effectiveness analysis of ondansetron versus metoclopramide regimens. Pharmacoeconomics 1994; 5 (3): 227–37

    Article  PubMed  CAS  Google Scholar 

  8. Cunningham D, Gore M, Davidson N, et al. The real costs of emesis: an economic analysis of ondansetron vs metoclopramidein controlling emesis in patients receiving chemotherapyfor cancer. Eur J Cancer 1993; 29A (3): 303–6

    Article  PubMed  CAS  Google Scholar 

  9. Buxton MJ, O’Brien BJ. Economic evaluations of ondansetron: preliminary analysis using clinical trial data prior to pricesetting. Br J Cancer 1992; 66 Suppl. 19: S64–7

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Oscar Lambret, Lille, France

    Jacques Bonneterre & Caroline Bercez

Authors
  1. Jacques Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Bercez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonneterre, J., Bercez, C. Economics of Serotonin 5-HT3 Antagonists. Pharmacoeconomics 10, 433–434 (1996). https://doi.org/10.2165/00019053-199610040-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610040-00011

Keywords

Search

Navigation